Q2 25 EPS
$0.78
BEAT +35.94%
Est. $0.57
Q2 25 Revenue
$14.65B
BEAT +8.29%
Est. $13.53B
vs S&P Since Q2 25
-3.7%
TRAILING MARKET
PFE +11.1% vs S&P +14.8%
Market Reaction
Did PFE Beat Earnings? Q2 2025 Results
Pfizer delivered a standout second quarter of 2025, posting adjusted diluted EPS of $0.78 against a consensus estimate of $0.57, a beat of 35.94%, while revenue of $14.65 billion topped expectations by 8.29% and rose 10.3% year over year. The broad-b… Read more Pfizer delivered a standout second quarter of 2025, posting adjusted diluted EPS of $0.78 against a consensus estimate of $0.57, a beat of 35.94%, while revenue of $14.65 billion topped expectations by 8.29% and rose 10.3% year over year. The broad-based performance was anchored by remarkable momentum across key franchises, with Comirnaty gaining from higher U.S. Market share and international contractual deliveries, and Paxlovid benefiting from improved net pricing following the government agreement transition. Vyndaqel continued its steady climb, growing 21% operationally to $1.61 billion on expanding patient diagnosis. Cost discipline was equally notable, with both SI&A and R&D expenses declining 8% operationally, reinforcing Pfizer's ongoing restructuring progress. Looking ahead, the company reaffirmed full-year 2025 revenue guidance of $61.0 to $64.0 billion and lifted its adjusted EPS outlook by $0.10 to a range of $2.90 to $3.10, even as it absorbs a roughly $0.20 hit from a $1.35 billion IPR&D charge tied to its 3SBio licensing deal expected in Q3; for investors drawn to durable income-generating names, Pfizer's trajectory offers renewed conviction.
Key Takeaways
- • Vyndaqel family growth driven by strong demand and continuing uptake in patient diagnosis
- • Comirnaty growth from higher U.S. market share and international contractual deliveries
- • Paxlovid growth from higher U.S. net price following government agreement transition and favorable rebate accrual adjustments
- • Padcev growth from increased first-line urothelial cancer market share and U.S. wholesaler distribution model transition
- • Focused commercial execution and ongoing productivity improvements reducing SI&A spending
- • Operational efficiency gains from cost realignment program and R&D pipeline optimization
- • Favorable jurisdictional mix of earnings improving effective tax rate
PFE YoY Financials
Q2 2025 vs Q2 2024, source: SEC Filings
PFE Revenue by Segment
With YoY comparisons, source: SEC Filings
PFE Revenue by Geography
With YoY comparisons, source: SEC Filings
“Pfizer had another strong quarter of focused execution and we're pleased with our progress in advancing our R&D pipeline, driving our commercial performance and expanding our margins. We continue to strengthen our company for the future and we're confident in our ability to create further value for patients and our shareholders.”
— Albert Bourla, Q2 2025 Earnings Press Release
PFE Earnings Trends
PFE vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
PFE EPS Trend
Earnings per share: estimate vs actual
PFE Revenue Trend
Quarterly revenue: estimate vs actual
PFE Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q4 25 BEAT FY | $0.57 | $0.66 | +15.79% | $17.56B | +4.09% |
| FY Full Year | $3.12 | $3.22 | +3.08% | $62.58B | +1.11% |
| Q3 25 BEAT | $0.64 | $0.87 | +36.96% | $16.65B | +0.92% |
| Q2 25 BEAT | $0.57 | $0.78 | +35.94% | $14.65B | +8.29% |
| Q1 25 BEAT | $0.68 | $0.92 | +35.19% | $13.72B | -2.69% |
| Q4 22 BEAT FY | $1.05 | $1.14 | +8.57% | $24.29B | +0.02% |
| FY Full Year | — | $6.58 | — | $100.33B | — |